Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. The Company is in late stage development of NX-1207, a drug for benign prostatic hyperplasia (BPH). Nymox has a number of drugs in development for E. coli infection, Alzheimer's disease, oncology, and infectious disease. The Company markets NicAlert(TM) and TobacAlert(TM) tests for measuring tobacco product exposure, and AlzheimAlert(TM), a test to aid in the diagnosis of Alzheimer's disease.

Contact Information

9900 Cavendish Boulevard
St Laurent, QCH4M2V2

tel: 514-332-3222
fax: 514-332-2227


Investor Relations



Exchange: NASDAQ
Industry: Diagnostic Substances
Market Cap: $127.6M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.